Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00071409
Status:
COMPLETED
Last Update Posted:
2014-07-11
First Post:
2003-10-22
Brief Title:
Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
Sponsor:
Exsulin Corporation
Organization:
Exsulin Corporation
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Rising Dose Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Type I Diabetes Mellitus Patients
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Insulin is a chemical that the body needs in order to use or store sugar It is made by a type of cell called a beta cell which resides in an organ known as the pancreas Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made Sugar levels rise in the blood as a result INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas and to restore the ability to produce insulin in type 1 diabetic patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None